Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation

被引:12
作者
Fazavana, Judicael [1 ]
Brophy, Teresa M. [1 ]
Chion, Alain [1 ]
Cooke, Niamh [2 ]
Terraube, Virginie [2 ]
Cohen, Justin [3 ]
Parng, Chuenlei [3 ]
Pittman, Debra [4 ]
Cunningham, Orla [2 ]
Lambert, Matthew [2 ]
O'Donnell, James S. [1 ,5 ]
O'Sullivan, Jamie M. [1 ]
机构
[1] Royal Coll Surgeons Ireland, Irish Ctr Vasc Biol, Sch Pharm & Biomol Sci, Dublin, Ireland
[2] Pfizer, BioMed Design, Dublin, Ireland
[3] Pfizer, BioMed Design, Cambridge, MA USA
[4] Pfizer, Rare Dis Res Unit, Cambridge, MA USA
[5] St James Hosp, Natl Coagulat Ctr, Dublin, Ireland
关键词
clearance; glycosylation; low density lipoprotein receptor-related protein; PEGylation; von Willebrand factor; VON-WILLEBRAND-FACTOR; FACTOR-VIII; PHENOTYPE; SURVIVAL; INSIGHTS;
D O I
10.1111/jth.14785
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Previous studies have demonstrated that the A1A2A3 domains of von Willebrand factor (VWF) play a key role in regulating macrophage-mediated clearance in vivo. In particular, the A1-domain has been shown to modulate interaction with macrophage low-density lipoprotein receptor-related protein-1 (LRP1) clearance receptor. Furthermore, N-linked glycans within the A2-domain have been shown to protect VWF against premature LRP1-mediated clearance. Importantly, however, the specific regions within A1A2A3 that enable macrophage binding have not been defined. Objective and Methods To address this, we utilized site-directed PEGylation and introduced novel targeted N-linked glycosylation within A1A2A3-VWF and subsequently examined VWF clearance. Results Conjugation with a 40-kDa polyethylene glycol (PEG) moiety significantly extended the half-life of A1A2A3-VWF in VWF-/- mice in a site-specific manner. For example, PEGylation at specific sites within the A1-domain (S1286) and A3-domain (V1803, S1807) attenuated VWF clearance in vivo, compared to wild-type A1A2A3-VWF. Furthermore, PEGylation at these specific sites ablated binding to differentiated THP-1 macrophages and LRP1 cluster II and cluster IV in-vitro. Conversely, PEGylation at other positions (Q1353-A1-domain and M1545-A2-domain) had limited effects on VWF clearance or binding to LRP1.Novel N-linked glycan chains were introduced at N1803 and N1807 in the A3-domain. In contrast to PEGylation at these sites, no significant extension in half-life was observed with these N-glycan variants. Conclusions These novel data demonstrate that site specific PEGylation but not site specific N-glycosylation modifies LRP1-dependent uptake of the A1A2A3-VWF by macrophages. This suggests that PEGylation, within the A1- and A3-domains in particular, may be used to attenuate LRP1-mediated clearance of VWF.
引用
收藏
页码:1278 / 1290
页数:13
相关论文
共 31 条
  • [1] The von Willebrand factor A3 domain does not contain a metal ion-dependent adhesion site motif
    Bienkowska, J
    Cruz, M
    Atiemo, A
    Handin, R
    Liddington, R
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (40) : 25162 - 25167
  • [2] Clearance of von Willebrand factor
    Casari, C.
    Lenting, P. J.
    Wohner, N.
    Christophe, O. D.
    Denis, C. V.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 202 - 211
  • [3] Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia
    Casonato, Alessandra
    Gallinaro, Lisa
    Cattini, Maria Grazia
    Pontara, Elena
    Padrini, Roberto
    Bertomoro, Antonella
    Daidone, Viviana
    Pagnan, Antonio
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (08): : 1366 - 1372
  • [4] Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD
    Castaman, Giancarlo
    Lethagen, Stefan
    Federici, Augusto B.
    Tosetto, Alberto
    Goodeve, Anne
    Budde, Ulrich
    Batlle, Javier
    Meyer, Dominique
    Mazurier, Claudine
    Fressinaud, Edith
    Goudemand, Jenny
    Eikenboom, Jeroen
    Schneppenheim, Reinhard
    Ingerslev, Jorgen
    Vorlova, Zdena
    Habart, David
    Holmberg, Lars
    Pasi, John
    Hill, Frank
    Peake, Ian
    Rodeghiero, Francesco
    [J]. BLOOD, 2008, 111 (07) : 3531 - 3539
  • [5] N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance
    Chion, Alain
    O'Sullivan, Jamie M.
    Drakeford, Clive
    Bergsson, Gudmundur
    Dalton, Niall
    Aguila, Sonia
    Ward, Soracha
    Fallon, Padraic G.
    Brophy, Teresa M.
    Preston, Roger J. S.
    Brady, Lauren
    Sheils, Orla
    Laffan, Michael
    McKinnon, Thomas A. J.
    O'Donnell, James S.
    [J]. BLOOD, 2016, 128 (15) : 1959 - 1968
  • [6] Davies JA, 2008, J THROMB HAEMOST, V6, P97
  • [7] VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease
    Eikenboom, Jeroen
    Federici, Augusto B.
    Dirven, Richard J.
    Castaman, Giancarlo
    Rodeghiero, Francesco
    Budde, Ulrich
    Schneppenheim, Reinhard
    Batlle, Javier
    Canciani, Maria Teresa
    Goudemand, Jenny
    Peake, Ian
    Goodeve, Anne
    [J]. BLOOD, 2013, 121 (12) : 2336 - 2339
  • [8] Crystal structure of the von Willebrand factor A1 domain and implications for the binding of platelet glycoprotein Ib
    Emsley, J
    Cruz, M
    Handin, R
    Liddington, R
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (17) : 10396 - 10401
  • [9] Elevated factor VIII levels and risk of venous thrombosis
    Jenkins, P. Vince
    Rawley, Orla
    Smith, Owen P.
    O'Donnell, James S.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (06) : 653 - 663
  • [10] Significant gynecological bleeding in women with low von Willebrand factor levels
    Lavin, Michelle
    Aguila, Sonia
    Dalton, Niall
    Nolan, Margaret
    Byrne, Mary
    Ryan, Kevin
    White, Barry
    O'Connell, Niamh M.
    O'Sullivan, Jamie M.
    Di Paola, Jorge
    James, Paula D.
    O'Donnell, James S.
    [J]. BLOOD ADVANCES, 2018, 2 (14) : 1784 - 1791